ArticleJournal of managed care & specialty pharmacy2025
Call for the alignment of Medicare Part D formularies with clinical treatment guidelines for asthma.
Article in Journal of managed care & specialty pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Costs of Single Maintenance and Reliever Therapy vs Traditional Therapy for Asthma.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Global Initiative for Asthma, the most widely cited international guidelines for asthma management, currently recommends the use of maintenance and reliever therapy with an inhaled corticosteroid-formoterol inhaler based on evidence showing reductions in asthma exacerbations and hospitalizations vs short-acting relievers alone. A review of Medicare Part D plans based on a Kaiser Family Foundation report reveals that the formulary design of many plans is not aligned with this recommendation, resulting in restricted prescriber adherence to the guidelines and limited patient access to standard-of-care treatments. To improve clinical outcomes, it is key that Medicare Part D plans minimize barriers to access through prioritization of inhaled corticosteroid-formoterol regimens as preferred formulary agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.